AKT1 and ovarian cancer: Continuing from these mechanistic findings, we could furthermore demonstrate that a pharmacological therapy combining the targeted inhibition of DYRK1B with that of PI3K/mTOR/AKT has strong effects on Hh/GLI signaling and on cell growth of DYRK1B-amplified pancreatic and ovarian cancer cells.